Brestoff Jonathan R, Kim Brian S, Saenz Steven A, Stine Rachel R, Monticelli Laurel A, Sonnenberg Gregory F, Thome Joseph J, Farber Donna L, Lutfy Kabirullah, Seale Patrick, Artis David
1] Jill Roberts Institute for Research in IBD, Joan and Sanford I. Weill Department of Medicine, Department of Microbiology and Immunology, Weill Cornell Medical College, Cornell University, New York, New York 10021, USA [2] Department of Microbiology and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Department of Microbiology and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Nature. 2015 Mar 12;519(7542):242-6. doi: 10.1038/nature14115. Epub 2014 Dec 22.
Obesity is an increasingly prevalent disease regulated by genetic and environmental factors. Emerging studies indicate that immune cells, including monocytes, granulocytes and lymphocytes, regulate metabolic homeostasis and are dysregulated in obesity. Group 2 innate lymphoid cells (ILC2s) can regulate adaptive immunity and eosinophil and alternatively activated macrophage responses, and were recently identified in murine white adipose tissue (WAT) where they may act to limit the development of obesity. However, ILC2s have not been identified in human adipose tissue, and the mechanisms by which ILC2s regulate metabolic homeostasis remain unknown. Here we identify ILC2s in human WAT and demonstrate that decreased ILC2 responses in WAT are a conserved characteristic of obesity in humans and mice. Interleukin (IL)-33 was found to be critical for the maintenance of ILC2s in WAT and in limiting adiposity in mice by increasing caloric expenditure. This was associated with recruitment of uncoupling protein 1 (UCP1)(+) beige adipocytes in WAT, a process known as beiging or browning that regulates caloric expenditure. IL-33-induced beiging was dependent on ILC2s, and IL-33 treatment or transfer of IL-33-elicited ILC2s was sufficient to drive beiging independently of the adaptive immune system, eosinophils or IL-4 receptor signalling. We found that ILC2s produce methionine-enkephalin peptides that can act directly on adipocytes to upregulate Ucp1 expression in vitro and that promote beiging in vivo. Collectively, these studies indicate that, in addition to responding to infection or tissue damage, ILC2s can regulate adipose function and metabolic homeostasis in part via production of enkephalin peptides that elicit beiging.
肥胖是一种受遗传和环境因素调控的日益普遍的疾病。新出现的研究表明,包括单核细胞、粒细胞和淋巴细胞在内的免疫细胞可调节代谢稳态,且在肥胖状态下会失调。2型固有淋巴细胞(ILC2s)可调节适应性免疫以及嗜酸性粒细胞和替代性活化巨噬细胞反应,最近在小鼠白色脂肪组织(WAT)中被发现,它们可能在其中发挥限制肥胖发展的作用。然而,ILC2s尚未在人类脂肪组织中被鉴定出来,且ILC2s调节代谢稳态的机制仍不清楚。在此,我们在人类WAT中鉴定出ILC2s,并证明WAT中ILC2反应降低是人类和小鼠肥胖的一个保守特征。发现白细胞介素(IL)-33对于维持WAT中的ILC2s以及通过增加热量消耗来限制小鼠肥胖至关重要。这与WAT中解偶联蛋白1(UCP1)(+)米色脂肪细胞的募集有关,这一过程称为米色化或褐变,可调节热量消耗。IL-33诱导的米色化依赖于ILC2s,并且IL-33处理或转移由IL-33引发的ILC2s足以独立于适应性免疫系统、嗜酸性粒细胞或IL-4受体信号传导驱动米色化。我们发现ILC2s产生甲硫氨酸脑啡肽肽,其可直接作用于脂肪细胞以在体外上调Ucp1表达,并在体内促进米色化。总的来说,这些研究表明,除了对感染或组织损伤做出反应外,ILC2s还可以部分通过产生引发米色化的脑啡肽肽来调节脂肪功能和代谢稳态。